Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo

International Journal of Cancer

Volumn 131, Issue 5, 2012, Pages

  Furuta, Hiroyuki ^a   Osawa, Kenji ^a   Shin, Masashi ^b   Ishikawa, Ayataka ^a   Matsuo, Kou ^a   Khan, Masud ^c   Aoki, Kazuhiro ^c   Ohya, Keiichi ^c   Okamoto, Masato ^d   Tominaga, Kazuhiro ^a   Takahashi, Tetsu ^a   Nakanishi, Osamu ^a   Jimi, Eijiro ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone invasion; NBD peptide; NF B; Oral squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT NBD PEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN INHIBITOR; SERINE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WILD TYPE NBD PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER INHIBITION; CANCER INVASION; CANCER LOCALIZATION; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STROMA CELL; UPREGULATION; ZYGOMA;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; BONE RESORPTION; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B PROTEINS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; MALE; MICE; MICE, INBRED C3H; MOUTH NEOPLASMS; NF-KAPPA B; PEPTIDES; PHOSPHORYLATION; PROTEIN TRANSPORT; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863186047     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27435     Document Type: Article

References (38)

1. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010;28:3336-43.
2. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54.
3. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009;6:266-77.
4. Jimi E, Furuta H, Matsuo K, Tominaga K, Takahashi T, Nakanishi O. The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis 2011;17: 462-8.
5. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54. (Pubitemid 29122073)
6. Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K, Nguyen ST, Miki Y, Iimura T, Himeno A, Akashi T, Yamada-Okabe H, et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol 2010;176:968-80.
7. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-7. (Pubitemid 36532608)
8. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423: 337-42. (Pubitemid 40852708)
9. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109:S81-96.
10. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009;27: 693-733.
11. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab 2011;13:11-22.
12. Pacifico F, Leonardi A. NF-κB in solid tumors. Biochem Pharmacol 2006;72:1142-52.
13. Arsura M, Cavin LG. Nuclear factor-κB and liver carcinogenesis. Cancer Lett 2005;229:157-69.
14. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011;12:715-23.
15. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-24. (Pubitemid 38796853)
16. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004;279:37219-22. (Pubitemid 39195425)
17. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 2004;10:6821-9. (Pubitemid 39383030)
18. He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D, Chen W. The NF-κB inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009;9:343.
19. Sakamoto K, Hikiba Y, Nakagawa H, Hayakawa Y, Yanai A, Akanuma M, Ogura K, Hirata Y, Kaestner KH, Omata M, Maeda S. Inhibitor of κB kinase beta regulates gastric carcinogenesis via interleukin-1α expression. Gastroenterology 2010; 139:226-38.e6.
20. May MJ, D'Acquisto F, Madge LA, Glöckner J, Pober JS, Ghosh S. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 2000;289:1550-4.
21. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-κB determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9:625-36. (Pubitemid 34273792)
22. Nomura T, Shibahara T, Katakura A, Matsubara S, Takano N. Establishment of a murine model of bone invasion by oral squamous cell carcinoma. Oral Oncol 2007;43:257-62. (Pubitemid 46228010)
23. Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, Okamoto M, Sato M, Yu G, Guo C, Shibahala T. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clin Cancer Res 2005;11: 2713-9. (Pubitemid 40569473)
24. Voll RE, Jimi E, Phillips RJ, Barber DF, Rincon M, Hayday AC, Flavell RA, Ghosh S. NF-κB activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity 2000;13:677-89.
25. Shin M, Kadowaki T, Iwata J, Kawakubo T, Yamaguchi N, Takii, Tsukuba T, Yamamoto K. Association of cathepsin E with tumor growth arrest through angiogenesis inhibition and enhanced immune responses. Biol Chem 2007; 388:1173-81. (Pubitemid 350059628)
26. Maruyama T, Fukushima H, Nakao K, Shin M, Yasuda H, Weih F, Doi T, Aoki K, Alles N, Ohya K, Hosokawa R, Jimi E. Processing of the NF-κB2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation. J Bone Miner Res 2010;25:1058-67.
27. Yang F, Tang E, Guan K, Wang CY. IKKβ plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 2003;170:5630-5. (Pubitemid 36617854)
28. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A, Doi T, Saiki I. Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003;278:36916-23. (Pubitemid 37140026)
29. Sasaki CY, Barberi TJ, Ghosh P, Longo DL. Phosphorylation of RelA/p65 on serine 536 defines an IκBα-independent NF-κB pathway. J Biol Chem 2005;280:34538-47. (Pubitemid 41504584)
30. Shin M, Matsuo K, Tada T, Fukushima H, Furuta H, Ozeki S, Kadowaki T, Yamamoto K, Okamoto M, Jimi E. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Carcinogenesis 2011;32:1634-1640.
31. Nakayama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor κB, IκB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001;92: 3037-44. (Pubitemid 33136198)
32. Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999;59:3495-504. (Pubitemid 29334514)
33. Duffey DC, Chen Z, Dong G,Ondrey FG, Wolf JS, Brown K, Siebenlist U, Van Waes C. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-74. (Pubitemid 29334510)
34. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T. Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 1998;273:8799-805. (Pubitemid 28176159)
35. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 2000;148:333-42. (Pubitemid 30078245)
36. Naugler WE, Karin M. NF-κB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008;18:19-26.
37. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor κB activation. Endocrinology 2006;147: 5699-707. (Pubitemid 44833486)
38. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 1996; 87:565-76. (Pubitemid 26374329)